Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Interim Budget 2024: Textile and apparel industry seeks tax incentives, infra boost for growth
- Centre to boost EV infra, new bio-manufacturing scheme in the offing: FM
- Education Budget 2023: Edtech sector welcomes new nursing colleges, teacher training initiatives
- Budget 2024 Live Updates: ‘Want to simplify approach to taxation’, says Nirmala Sitharaman on Lower capital gains